Trial Profile

A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Nov 2024 According to a GenVivo media release, the company will present a poster highlighting the data from the study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-10, in Houston, TX.
06 Nov 2024 Status changed from active, no longer recruiting to completed.
27 Jun 2024 According to a GenVivo media release, the company look forward to advancing to the expansion phase once the appropriate dose is identified.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com